Intellectus Partners, LLC Bio Line Rx Ltd. Transaction History

Intellectus Partners, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.98 - $3.06 $56,430 - $87,210	-28,500 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$2.65 - $3.35 $31,800 - $40,200	-12,000 Reduced 29.63%	28,500 $78,000
Q1 2021 May 17, 2021	BUY	$2.38 - $4.0 $96,390 - $162,000	40,500 New	40,500 $113,000

3.35M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $13.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Intellectus Partners, LLC with notifications on news.